Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod [Phase 2]
Phase 2 clinical trial evaluating a dendritic cell/tumor fusion vaccine with GM-CSF and Imiquimod for ovarian cancer, primary peritoneal can…
-
CLINICAL_TRIALS research · 2024-06-06Clinical Trial Update: Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test
A clinical trial is evaluating capillary home-sampling combined with a protein biomarker test for early detection of relapse in ovarian canc…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating neo-adjuvant pembrolizumab in primary stage IV ovarian cancer with peritoneal or fallopian tube involvement. The …
-
CLINICAL_TRIALS research · 2024-05-20Clinical Trial Update: RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression [Phase 2]
A Phase 2 clinical trial update for RC48 (disitamab vedotin) in platinum-sensitive recurrent ovarian cancer expressing HER2; the study is cu…
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab [Phase 2]
Phase 2 trial evaluating weekly ixabepilone with or without biweekly bevacizumab in epithelial ovarian cancer and related peritoneal cancers…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer [NA]
The LCC-CARIS-01 trial focusing on molecular profiling in gynecologic cancers has completed. The study included epithelial ovarian cancer, p…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib [Phase 3]
Phase 3 rollover study CATCH-R provides continued access to rucaparib for eligible patients with metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer [Phase 1]
The Phase 1 study of KHK2866, an HB-EGF–targeting antibody, in advanced solid tumors and ovarian cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial of DSP-7888 Dosing Emulsion in combination with immune checkpoint inhibitors in adults with advanced solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in participants with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.
-
FDA approval · 2024-03-22FDA Approved: ELAHERE — Supplemental Application (ImmunoGen, Inc.)
FDA approves a supplemental application for ELAHERE (mirvetuximab soravtansine) from ImmunoGen, Inc. The approval updates the labeling to re…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating mirvetuximab soravtansine in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, or pem…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor [Phase 2]
Phase 2 clinical trial evaluating a genetic profile–guided treatment strategy for ovarian cancer patients who previously received a PARP inh…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]
Phase 2 trial evaluating olaparib given before surgery and chemotherapy in ovarian, primary peritoneal, and fallopian tube cancers; current …
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating avelumab with or without entinostat in advanced epithelial ovarian cancer and peritoneal cancer has completed; re…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pazopanib hydrochloride with paclitaxel and carboplatin in patients with refractory or resistant ovari…
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi [Phase 2]
Phase 2 trial evaluating fluzoparib with or without apatinib in platinum-sensitive relapsed ovarian cancer previously treated with PARP inhi…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). [Phase 2]
Phase 2 trial of pembrolizumab with paclitaxel and carboplatin in advanced epithelial ovarian cancer (and fallopian tube/peritoneal cancers)…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) [Phase 3]
A Phase 3 trial of Upifitamab Rilsodotin (Upifitamab Rilsodotin) in maintenance therapy for platinum-sensitive recurrent ovarian cancer has …
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating the addition of tremelimumab to olaparib for recurrent ovarian, fallopian tube, or primary peritoneal cancer; the s…
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: BrUOG 390: Neoadjuvant Treatment With Talazoparib [Phase 1]
Phase 1 neoadjuvant study of talazoparib in BRCA1/BRCA2 mutation-associated cancers ( ovarian/fallopian tube high-grade serous carcinoma) ha…
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors [Phase 1]
Phase 1 results for a study combining the TORC1/2 inhibitor MLN0128 (sapanisertib) with bevacizumab in adults with recurrent glioblastoma or…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial [Phase 2, Phase 3]
Trial update for intraperitoneal therapy with carboplatin in epithelial ovarian cancer and related conditions; the study has completed phase…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) [Phase 1]
Phase 1 trial evaluating autologous T cells with or without cyclophosphamide and fludarabine for recurrent or persistent advanced ovarian ep…
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial update evaluating gemcitabine hydrochloride with or without the WEE1 inhibitor adavosertib in patients with recurrent…